Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 2/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506308 | 0.86 | KIF11 (0.44) | KIF11MLYCDOPRD1OPRM1CYP1A2 | |
| SCHEMBL6529219 | 0.86 | KIF11 (0.41) | KIF11MLYCDCYP1A2HSP90AA1HSP90AB1 | |
| SCHEMBL5739761 | 0.85 | ACHE (0.37) | KIF11BLM | |
| SCHEMBL6504028 | 0.81 | MAPK14 (0.41) | — | |
| SCHEMBL5741839 | 0.79 | RXRA (0.37) | KIF11 | |
| SCHEMBL6529416 | 0.77 | PDK2 (0.36) | KIF11 | |
| SCHEMBL6510139 | 0.74 | KMT2A (0.41) | KIF11MLYCD | |
| SCHEMBL5739318 | 0.73 | KIF11 (0.32) | KIF11 | |
| SCHEMBL5739313 | 0.73 | PDE4B (0.33) | — | |
| SCHEMBL5739316 | 0.73 | PDE4B (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | BAYER HEALTHCARE AG (DE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | HTT, HMOX1, SNCA | KIF11 2553/4885MLYCD 3859/4885OXTR 3196/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | KIF11 2866/4885MLYCD 2538/4885OXTR 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.